• A-1331852: Precision BCL-XL Inhibition

  2026-09-08

  A-1331852 is a selective BCL-XL inhibitor for mapping apoptotic dependence, validating BCL-XL–BIM complex disruption, and testing senolytic strategies in cancer models. This guide translates published BH3-mimetic findings into practical dose-response, apoptosis, and troubleshooting workflows.

• hCG, H3K27 Methylation, and CXCL10 in Decidua

  2026-09-08

  The reference study shows that human chorionic gonadotropin suppresses CXCL10 in human decidual stromal cells by promoting EZH2-dependent H3K27 trimethylation at the CXCL10 promoter. This connects placental endocrine signaling with chromatin control of immune-cell recruitment and provides a mechanistic framework for studying maternal–fetal immune tolerance.

• Biotin-16-UTP: From RNA Labels to Mechanism

  2026-09-07

  Biotin-16-UTP connects biotin-labeled RNA synthesis with mechanistic questions in cancer biology. Using the LINC02870–EIF4G1–SNAIL axis in hepatocellular carcinoma as an anchor, this article outlines how translational researchers can use affinity-enabled RNA workflows to validate RNA-protein interactions while managing assay, interpretation, and clinical-translation risks.

• BAY-826: A Causal Lens on Retinal Signaling

  2026-09-07

  Retinal neurovascular biology is increasingly understood as a coordinated conversation among angiopoietin signaling, Müller cells, PEDF, and neuronal survival. This thought-leadership article positions BAY-826 as a hypothesis-testing research tool rather than an assumed pathway solution, outlining how translational teams can connect chemical perturbation to target engagement, co-culture phenotypes, and causal rescue experiments.

• RNASEH1-AS1 as an HCC Biomarker

  2026-09-05

  The reference study integrates TCGA-based bioinformatics, risk modeling, and cell-based validation to identify RNASEH1-AS1 as a prognostic and potentially oncogenic lncRNA in hepatocellular carcinoma. Its findings connect RNASEH1-AS1 expression with tumor grade, survival, immune-cell infiltration, ribosome-related gene networks, and DKC1-dependent RNA stability, while also defining experimental directions for further mechanistic work.

• AI-10-49: An Assay-First AML Strategy

  2026-09-04

  AI-10-49 is a selective CBFβ-SMMHC inhibitor for dissecting fusion-driven acute myeloid leukemia. This assay-first guide connects target engagement, RUNX1 chromatin restoration, and the N-MYC/eIF4G1 survival program to practical experimental decisions.

• Gramine–MTDH Ferroptosis in Triple-Negative Breast Cancer

  2026-09-04

  This study identifies gramine as a potential inhibitor of triple-negative breast cancer and defines a CUL3–MTDH regulatory mechanism that promotes ferroptosis. Its combination of chemical screening, target-validation assays, ferroptosis rescue experiments, and tumor models provides a useful framework for studying ubiquitin-regulated cell death in TNBC.

• Cy5 Goat Anti-Mouse IgG (H+L) Antibody Guide

  2026-09-03

  The Cy5 Goat Anti-Mouse IgG (H+L) Antibody is a Cy5-conjugated secondary antibody for sensitive mouse IgG detection in IHC, ICC, and flow cytometry. Its affinity-purified polyclonal design supports signal amplification, while defined buffer and storage conditions guide reproducible handling.

• Beyond Viability: Interpreting Cancer Drug Responses

  2026-09-03

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a framework that separates growth inhibition from cell killing, helping researchers design more informative response assays and interpret drug effects across time.

• Brain-to-Spinal Circuits Control Mechanical Allodynia

  2026-09-02

  This Cell Reports study identifies a contralateral lPBN–hypothalamus–spinal pathway that regulates both the laterality and persistence of mechanical allodynia in mice. Its combination of circuit mapping, cell-type-specific perturbation, behavioral models, and κ-opioid receptor manipulation provides a framework for studying descending pain control and opioid receptor signaling research.

• Epinephrine Bitartrate: Adrenergic Research Guide

  2026-09-02

  Epinephrine Bitartrate is a non-selective adrenergic receptor agonist for controlled studies of α- and β-receptor signaling. This guide separates product-dossier specifications from peer-reviewed receptor-binding evidence and provides practical assay boundaries.

• Foretinib: Separating Growth Arrest from Cell Death

  2026-09-01

  Foretinib (GSK1363089) is a multikinase research tool for studying Met- and VEGFR-dependent cancer biology. This guide moves beyond endpoint-only workflows by showing how to distinguish tumor cell growth inhibition, cell death, and motility effects in a time-resolved experimental design.

• Procainamide Hydrochloride in Multimodal Assays

  2026-09-01

  Procainamide Hydrochloride is more than a cardiac sodium channel blocker: it can support mechanism-separated studies spanning Nav1.5 electrophysiology, epigenetic regulation, and immune-cell phenotyping. This article presents an assay framework that connects these domains without conflating their evidence levels.

• Phosbind Acrylamide for Phosphorylation Analysis

  2026-08-31

  Phosbind Acrylamide enables antibody-free, phosphate-dependent mobility analysis in SDS-PAGE, making it useful for kinase assays, signaling time courses, and circadian-clock studies. This guide translates the ISX-9–CaMKIIδ–BMAL1 findings into practical gel controls, workflow decisions, and troubleshooting steps.

• EZ Cap Cy5 Firefly Luciferase mRNA Workflow

  2026-08-31

  Track both where an mRNA goes and whether it produces protein with one dual-reporter transcript. This practical guide connects Cy5 imaging, luciferase quantification, and delivery optimization for nanoparticle, cellular, and translational workflows.

7777 records 1/519 page Next 12345 下5页 Last page